Design Therapeutics, Inc. (DSGN) has disclosed a new risk, in the Capital Markets category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Design Therapeutics, Inc. faces significant business risks due to international trade policies, including tariffs, sanctions, and trade barriers. The company’s reliance on third-party suppliers in countries like China exposes it to potential disruptions in its supply chain and increased costs, particularly for active pharmaceutical ingredients. The dynamic and unpredictable trade landscape, characterized by new U.S. tariffs and retaliatory measures from foreign governments, could delay development timelines and hinder the establishment of cost-effective production capabilities. These factors may reduce investor confidence, complicate compliance with trade regulations, and limit the company’s ability to compete internationally, ultimately affecting its financial condition and growth prospects.
The average DSGN stock price target is $8.50, implying 110.40% upside potential.
To learn more about Design Therapeutics, Inc.’s risk factors, click here.